Jane Street Group, LLC Reata Pharmaceuticals Inc Put Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 17, 2022	BUY	$24.12 - $39.6 $1.37 Million - $2.25 Million	56,800 Added 172.12%	89,800 $2.94 Million
Q4 2021 Feb 15, 2022	SELL	$25.61 - $110.96 $568,542 - $2.46 Million	-22,200 Reduced 40.22%	33,000 $870,000
Q3 2021 Nov 16, 2021	BUY	$100.0 - $143.02 $820,000 - $1.17 Million	8,200 Added 17.45%	55,200 $5.55 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $712,257 - $1.38 Million	-9,100 Reduced 16.22%	47,000 $6.65 Million
Q1 2021 May 18, 2021	BUY	$94.25 - $132.81 $3.56 Million - $5.02 Million	37,800 Added 206.56%	56,100 $5.59 Million
Q4 2020 Feb 17, 2021	SELL	$102.03 - $184.62 $2.61 Million - $4.73 Million	-25,600 Reduced 58.31%	18,300 $2.26 Million
Q3 2020 Nov 17, 2020	BUY	$93.53 - $163.34 $2.98 Million - $5.21 Million	31,900 Added 265.83%	43,900 $4.28 Million
Q2 2020 Aug 17, 2020	SELL	$126.3 - $176.56 $5.3 Million - $7.42 Million	-42,000 Reduced 77.78%	12,000 $1.87 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $6.47 Million - $12.9 Million	52,100 Added 2742.11%	54,000 $7.79 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $141,683 - $414,048	1,900 New	1,900 $388,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.